Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 18/20 | 0.62 |
| ▸ | TACR2 | P21452 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.51 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6534501 | 1.00 | TACR3 (0.62) | TACR3TACR2MEN1CACNA1BAPBA1 | |
| SCHEMBL6534518 | 0.92 | TACR3 (0.72) | TACR3TACR2 | |
| SCHEMBL6534519 | 0.92 | TACR3 (0.72) | TACR3TACR2 | |
| SCHEMBL6534463 | 0.85 | TACR3 (0.60) | TACR3TACR2MEN1CACNA1BAPBA1 | |
| SCHEMBL6534466 | 0.85 | TACR3 (0.60) | TACR3TACR2MEN1CACNA1BAPBA1 | |
| SCHEMBL6534359 | 0.85 | TACR3 (0.62) | TACR3TACR2MEN1KMT2A | |
| SCHEMBL6534365 | 0.85 | TACR3 (0.62) | TACR3TACR2MEN1KMT2A | |
| SCHEMBL6534618 | 0.83 | TACR3 (0.61) | TACR3TACR2 | |
| SCHEMBL6534620 | 0.83 | TACR3 (0.61) | TACR3TACR2 | |
| SCHEMBL6534624 | 0.83 | DHODH (0.62) | TACR3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0983243-B1 | NOVEL QUINOLINE- AND NAPHTHALENECARBOXAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF INHIBITING CALPAIN | SMITHKLINE BEECHAM CORP (US) | 2004-06-16 | — | — | EP | disclosed |
| US-6100267-A | ENZYME INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISORDERS, STROKES, TRAUMATIC BRAIN INJURY, CATARACTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-08 | — | — | US | disclosed |